Sleep apnea affects an estimated 50 million adults in the United States, yet roughly 80% of them don’t know it. Left untreated, it’s linked to serious downstream conditions: cardiovascular disease, metabolic disorders, cognitive decline, and more. Even for those who do get diagnosed, the path to care has historically been slow and fragmented. In-person sleep clinic waitlists can stretch several months, and once a patient is finally on treatment, ongoing compliance monitoring tends to fall through the cracks.
Ognomy was built to solve this problem.
Introducing Ognomy Sleep
Ognomy is an end-to-end virtual sleep medicine platform that manages the full patient journey, from referral and home sleep testing all the way through diagnosis, treatment, and ongoing follow-up care. Board-certified sleep medicine specialists are available across all 50 states, and because the platform is therapy-agnostic, patients get the treatment that’s right for them, including options like CPAP, GLP-1 medications, and oral appliances. Compliance monitoring and clinician communication are built into the model from the start, which means patients stay engaged with their care in a way that the traditional, fragmented approach to sleep medicine has rarely been able to deliver.
Why We’re Excited
Sleep medicine is at an inflection point. Rising consumer focus on longevity and sleep health, the rapid adoption of wearables, and the recent FDA approval of Zepbound (GLP-1) as the first drug to treat obstructive sleep apnea are all converging at once, and there remains a massive undiagnosed gap that we believe is just beginning to close.
Virtual care is a natural fit for this moment. The widespread adoption of home sleep tests means most cases can now be diagnosed and managed entirely remotely, and Ognomy’s virtual-first model removes both the geographic and financial barriers that have historically kept so many patients from getting care, while making the process more approachable for those who have been put off by the traditional diagnostic experience. Ognomy’s growing partner ecosystem spanning pharma, device manufacturers, and clinical partners adds to that, giving patients access to a broader range of treatment options and strengthening the quality of care Ognomy can deliver.
Sleep apnea is also highly comorbid with obesity, diabetes, and cardiovascular disease. As payers and health systems focus on value-based care and population health, the data Ognomy collects across the patient journey has the potential to support outcomes-driven programs and opens a compelling long-term opportunity to play a significant role in the broader cardiometabolic patient journey.
We’re thrilled to partner with the Ognomy team as they continue to expand access to sleep care. The underlying focus of Catalyst’s healthcare thesis is to enable high-quality care, and Ognomy’s mission aligns deeply with that goal. We’re excited for what’s ahead.